Millipore Sigma Vibrant Logo

529576 InSolution™ PP2 - Calbiochem

InSolution™ PP2, 172889-27-9, is a 10 mM solution of PP2 (Cat. No. 529573) in DMSO. A potent, reversible, ATP-competitive, inhibitor of the Src family of protein tyrosine kinases.

InSolution™ PP2 - Calbiochem MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
Primary Target: p56lck
View Products on Sigmaaldrich.com
529576
View Pricing & Availability

Overview

Replacement Information

Key Spec Table

Empirical Formula
C₁₅H₁₆ClN₅

Pricing & Availability

Catalogue Number AvailabilityPackaging Qty/Pack Price Quantity
529576-1MG
Retrieving availability...
—
Limited Availability Limited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      		 Plastic ampoule 1 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      —
      Request Pricing
      		 —
      Description
      Catalogue Number529576
      Brand Family Calbiochem®
      References
      ReferencesHanke, J.H., et al. 1996. J. Biol. Chem. 271, 695.



      Selected Citations
      Lee, J., et al. 2009. Cell Stem Cell 5, 76.
      Product Information
      ATP CompetitiveY
      FormClear and colorless liquid
      FormulationA 10 mM (1 mg/331 µl) solution of PP2 (Cat. No. 529573) in DMSO.
      Hill FormulaC₁₅H₁₆ClN₅
      Chemical formulaC₁₅H₁₆ClN₅
      HS Code3824 99 79
      ReversibleY
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      ApplicationInSolution™ PP2, 172889-27-9, is a 10 mM solution of PP2 (Cat. No. 529573) in DMSO. A potent, reversible, ATP-competitive, inhibitor of the Src family of protein tyrosine kinases.
      Biological Information
      Primary Targetp56lck
      Primary Target IC<sub>50</sub>4 nM, 5 nM, 5 nM, 100 nM, against p56lck, p59fynT, Hck , and Src, respectively; 600 nM against anti-CD3-stimulated tyrosine phosphorylation of human T cells
      Purity≥95% by HPLC
      Physicochemical Information
      Cell permeableN
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      R PhraseR: 36/37/38

      Irritating to eyes, respiratory system and skin.
      S PhraseS: 23-26-36

      Do not breathe fumes.
      In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
      Wear suitable protective clothing.
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Blue Ice Only
      Toxicity Irritant
      Storage -20°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot, purge with inert gas, and freeze (-20°C).
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      529576-1MG 07790788051211

      Documentation

      Required Licenses

      Title
      PRODUCTO REGULADO POR LA SECRETARÍA DE SALUD

      InSolution™ PP2 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      InSolution™ PP2 - Calbiochem Certificates of Analysis

      TitleLot Number
      529576

      References

      Reference overview
      Hanke, J.H., et al. 1996. J. Biol. Chem. 271, 695.



      Selected Citations
      Lee, J., et al. 2009. Cell Stem Cell 5, 76.

      Citations

      Title
    • Elke Heiss, et al. (2006) Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2. Blood in press,.
    • Farahdiba Jafri, et al. (2006) Constitutive ERK1/2 activation by a chimeric neurokinin NK1 receptor-beta-arrestin1 fusion protein: Probing the composition and function of the G protein-coupled receptor 'signalsome'. Journal of Biological Chemistry in press,.
    • Ana Olivera, et al. (2006) IgE-dependent activation of sphingosine kinase 1 and 2 and secretion of sphingosine-1-phosphate requires Fyn kinase and contributes to mast cell responses. Journal of Biological Chemistry 281, 2515-2525.
    • Ellen J. Tisdale and Cristina R. Artalejo. (2006) Src-dependent aPKC/ tyrosine phosphorylation is required for aPKC/ association with Rab2 and glyceraldehyde-3-phosphate dehydrogenase on Pre-golgi intermediates. Journal of Biological Chemistry 281, 8436-8442.
    • Malcolm A. Meyn, et al. (2005) Src family kinase activity is required for murine embryonic stem cell growth and differentiation. Molecular Pharmacology 68, 1320-1330.
    • Justin M. Summy, et al. (2005) AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Molecular Cancer Therapeutics 4, 1900-1911.
    • Jose G. Trevino, et al. (2005) Expression and activity of Src regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. Cancer Research 65, 7214-7222.
    • Xinbo Liao, et al. (2003) Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology 144, 1656-1663.
      		•
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision27-August-2008 RFH
      DescriptionA potent and selective inhibitor of the src family of tyrosine kinases. Its action is similar to PP1. Selectively inhibits p56lck (IC50 = 4 nM), p59fynT (IC50 = 5 nM), and Hck (IC50 = 5 nM) compared to other tyrosine kinases, such as EGF-R (IC50 = 480 nM), JAK2 (IC50 >50 µM) or ZAP-70 (IC50 >100 µM). Also potently inhibits anti-CD3-stimulated tyrosine phosphorylation of human T cells (IC50 = 600 nM).
      FormClear and colorless liquid
      FormulationA 10 mM (1 mg/331 µl) solution of PP2 (Cat. No. 529573) in DMSO.
      Intert gas (Yes/No) Packaged under inert gas
      Chemical formulaC₁₅H₁₆ClN₅
      Structure formulaStructure formula
      Purity≥95% by HPLC
      Storage Protect from light
      -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot, purge with inert gas, and freeze (-20°C).
      Toxicity Irritant
      ReferencesHanke, J.H., et al. 1996. J. Biol. Chem. 271, 695.



      Selected Citations
      Lee, J., et al. 2009. Cell Stem Cell 5, 76.
      Citation
    • Elke Heiss, et al. (2006) Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2. Blood in press,.
    • Farahdiba Jafri, et al. (2006) Constitutive ERK1/2 activation by a chimeric neurokinin NK1 receptor-beta-arrestin1 fusion protein: Probing the composition and function of the G protein-coupled receptor 'signalsome'. Journal of Biological Chemistry in press,.
    • Ana Olivera, et al. (2006) IgE-dependent activation of sphingosine kinase 1 and 2 and secretion of sphingosine-1-phosphate requires Fyn kinase and contributes to mast cell responses. Journal of Biological Chemistry 281, 2515-2525.
    • Ellen J. Tisdale and Cristina R. Artalejo. (2006) Src-dependent aPKC/ tyrosine phosphorylation is required for aPKC/ association with Rab2 and glyceraldehyde-3-phosphate dehydrogenase on Pre-golgi intermediates. Journal of Biological Chemistry 281, 8436-8442.
    • Malcolm A. Meyn, et al. (2005) Src family kinase activity is required for murine embryonic stem cell growth and differentiation. Molecular Pharmacology 68, 1320-1330.
    • Justin M. Summy, et al. (2005) AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Molecular Cancer Therapeutics 4, 1900-1911.
    • Jose G. Trevino, et al. (2005) Expression and activity of Src regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. Cancer Research 65, 7214-7222.
    • Xinbo Liao, et al. (2003) Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology 144, 1656-1663.
      		•